Search

Search Constraints

You searched for: Author/Creator Flaherty, Keith T.

Search Results

1. A first‐in‐human phase I, multicenter, open‐label, dose‐escalation study of the oral RAF/VEGFR‐2 inhibitor (RAF265) in locally advanced or metastatic melanoma independent from BRAF mutation status. (18th July 2017)

2. A novel multi-CDK inhibitor P1446A-05 restricts melanoma growth and produces synergistic effects in combination with MAPK pathway inhibitors. Issue 7 (2nd July 2016)

4. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (18th May 2015)

5. A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma. (18th May 2015)

6. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. (4th May 2018)

7. A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG‐ACRIN Cancer Research Group (EAQ152). Issue 7 (10th December 2021)

8. Academic Cancer Center Phase I Program Development. (17th March 2017)

9. Academic Cancer Center Phase I Program Development. (April 2017)

10. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group‐American College of Radiology Imaging Network (ECOG‐ACRIN) E2805. (23rd September 2021)